Q4 2022
Released Jun 8, 2022, before the open
10-K filed Jun 8, 2022, 69 days after period end · 0001764013-22-000059
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$47.17M-$47.17M derivedno prior Q4 2021 on fileN/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$32,956,000—
Free Cash Flowderived-$33,074,000—
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2018 |
|---|---|---|
| Net Income | -$47.17M | -$450.00 |
| EPS Diluted | — | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR